Envista (NYSE:NVST) Stock Gets Downgrade from Wall Street Zen

Envista (NYSE:NVST) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.

NVST has been the subject of several other reports. JPMorgan Chase & Co. raised shares of Envista from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $29.00 to $32.00 in a research report on Thursday, September 3rd. Piper Sandler dropped their price objective on Envista from $28.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, October 9th. Weiss Ratings reissued a “hold (c)” rating on shares of Envista in a research report on Tuesday, November 3rd. Zacks Research lowered Envista from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 5th. Finally, UBS Group boosted their target price on Envista from $27.00 to $29.00 and gave the stock a “neutral” rating in a research note on Thursday. Six equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $29.00.

Envista Stock Up 0.1%

Shares of Envista stock opened at $25.20 on Friday. Envista has a 52-week low of $18.77 and a 52-week high of $30.42. The company has a 50 day moving average of $24.38 and a 200 day moving average of $25.74. The company has a quick ratio of 2.10, a current ratio of 2.45 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $4.05 billion, a P/E ratio of 6.51, a P/E/G ratio of 1.20 and a beta of 0.94.

Envista (NYSE:NVST) last posted its quarterly earnings results on Wednesday, November 4th. The company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.36 by $0.04. Envista had a net margin of 22.01% and a return on equity of 8.26%. The company had revenue of $691.50 million during the quarter, compared to analysts’ expectations of $688.74 million. During the same quarter in the previous year, the business posted $0.32 EPS. The firm’s revenue was up 3.2% on a year-over-year basis. As a group, research analysts forecast that Envista will post 1.56 EPS for the current fiscal year.

Insiders Place Their Bets

In other Envista news, SVP Mischa Reis sold 8,000 shares of the company’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $27.50, for a total value of $220,000.00. Following the completion of the transaction, the senior vice president owned 27,321 shares in the company, valued at $751,327.50. This represents a 22.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.99% of the stock is currently owned by company insiders.

Institutional Trading of Envista

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Diversified Trust Co purchased a new position in shares of Envista during the third quarter worth about $755,000. AlphaCore Capital LLC purchased a new position in Envista during the 3rd quarter worth $330,000. Hohimer Wealth Management LLC lifted its position in Envista by 6.3% in the third quarter. Hohimer Wealth Management LLC now owns 10,934 shares of the company’s stock valued at $257,000 after purchasing an additional 651 shares during the period. Brighton Jones LLC lifted its position in Envista by 36.0% in the third quarter. Brighton Jones LLC now owns 20,908 shares of the company’s stock valued at $491,000 after purchasing an additional 5,540 shares during the period. Finally, CenterBook Partners LP boosted its holdings in Envista by 2.2% in the 3rd quarter. CenterBook Partners LP now owns 26,441 shares of the company’s stock valued at $621,000 after purchasing an additional 581 shares in the last quarter.

Envista News Roundup

Here are the key news stories impacting Envista this week:

• Positive Sentiment: Q3 results topped expectations: Envista reported adjusted earnings of $0.40 per share and revenue of $691.5 million, both above analyst estimates. Revenue rose 3.2% year over year, while earnings increased from $0.32 a year earlier. Envista tops Q3 earnings and revenue estimates
• Positive Sentiment: 2026 outlook raised: Management lifted its earnings outlook, citing pricing and productivity gains—an encouraging signal for near-term profitability. Q3 earnings-call highlights
• Positive Sentiment: UBS raised its price target from $27 to $29, though it maintained a Neutral rating. UBS Group stock recommendations
• Neutral Sentiment: Some valuation commentary argues NVST may be undervalued following a substantial prior decline, while a Zacks article highlights its momentum score. These are analyst perspectives rather than new company developments. Envista could be undervalued on earnings guidance
• Negative Sentiment: China remains a forward-looking risk: Procurement reforms there could weigh on margins as Envista enters 2027, potentially offsetting some benefits from pricing and productivity improvements. Q3 earnings-call highlights

Envista Company Profile

Envista Holdings Corporation is a dental products and technology company that develops and supplies tools and services for dental professionals. Its offerings span implant dentistry, orthodontics, digital imaging, restorative care and other clinical applications.

The company’s products include dental implants and related treatment systems, orthodontic brackets and clear aligners, imaging equipment and software, and restorative and endodontic materials. Its brands include Nobel Biocare, Ormco, DEXIS, Kerr and KaVo.

Envista was formed in 2019 through the separation of Danaher Corporation’s dental businesses.